• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Kuhnl, A.
    Roddie, C.
    Kirkwood, A. A.
    Tholouli, E.
    Menne, T.
    Patel, Amit
    Besley, C.
    Chaganti, S.
    Sanderson, R.
    O'Reilly, M.
    Norman, J.
    Osborne, W.
    Bloor, Adrian
    Lugthart, S.
    Malladi, R.
    Patten, P. E. M.
    Neill, L.
    Martinez-Cibrian, N.
    Kennedy, H.
    Phillips, Elizabeth H
    Jones, C.
    Sharplin, K.
    El-Sharkawi, D.
    Latif, A. L.
    Mathew, A.
    Uttenthal, B.
    Stewart, O.
    Marzolini, M. A. V.
    Townsend, W.
    Cwynarski, K.
    Ardeshna, K.
    Ardavan, A.
    Robinson, K.
    Pagliuca, A.
    Collins, G. P.
    Johnson, R.
    McMillan, A.
    Show allShow less
    Affiliation
    Department of Haematology, King's College Hospital, London, UK.
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    CD19 CAR-T have emerged as a new standard treatment for relapsed/refractory (r/r) large B-cell lymphoma (LBCL). CAR-T real-world (RW) outcomes published to date suggest significant variability across countries. We provide results of a large national cohort of patients intended to be treated with CAR-T in the UK. Consecutive patients with r/r LBCL approved for CAR-T by the National CAR-T Clinical Panel between December 2018 and November 2020 across all UK CAR-T centres were included. 404/432 patients were approved [292 axicabtagene ciloleucel (axi-cel), 112 tisagenlecleucel (tisa-cel)], 300 (74%) received the cells. 110/300 (38.3%) patients achieved complete remission (CR) at 6 months (m). The overall response rate was 77% (52% CR) for axi-cel, 57% (44% CR) for tisa-cel. The 12-month progression-free survival was 41.8% (axi-cel) and 27.4% (tisa-cel). Median overall survival for the intention-to-treat population was 10.5 m, 16.2 m for infused patients. The incidence of grade ≥3 cytokine release syndrome and neurotoxicity were 7.6%/19.6% for axi-cel and 7.9%/3.9% for tisa-cel. This prospective RW population of CAR-T eligible patients offers important insights into the clinical benefit of CD19 CAR-T in LBCL in daily practice. Our results confirm long-term efficacy in patients receiving treatment similar to the pivotal trials, but highlight the significance of early CAR-T failure.
    Citation
    Kuhnl A, Roddie C, Kirkwood AA, Tholouli E, Menne T, Patel A, et al. A national service for delivering CD19 CAR‐T in large B‐cell lymphoma – The UK real‐world experience. British Journal of Haematology. Wiley; 2022.
    Journal
    British Journal of Haematology
    URI
    http://hdl.handle.net/10541/625211
    DOI
    10.1111/bjh.18209
    PubMed ID
    35485402
    Additional Links
    https://dx.doi.org/10.1111/bjh.18209
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1111/bjh.18209
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.